POST-TEST

Oncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **In the Phase III DESTINY-Breast04 study evaluating trastuzumab deruxtecan (T-DXd) for previously treated HER2-low metastatic breast cancer, clinical benefit was seen in which of the following subgroups?**
   a. HR-positive breast cancer
   b. HR-negative breast cancer
   c. HER2-low breast cancer
   d. All of the above

2. **In DESTINY-Breast04, what clinical finding was reported among patients with different HER2-low immunohistochemistry (IHC) expression levels?**
   a. A significant difference in response between IHC 1+ and IHC 2+/ISH-negative
   b. No significant difference in response between IHC 1+ and IHC 2+/ISH-negative
   c. There was not an analysis conducted based on HER2-low IHC expression

3. **Sacituzumab govitecan is an antibody-drug conjugate indicated for certain locally advanced/metastatic breast cancers that targets which of the following biomarkers?**
   a. HER2
   b. HER3
   c. CDK4/6
   d. EGFR
   e. TROP2

4. **The Phase III DESTINY-Breast06 study evaluated T-DXd for which patient population?**
   a. Newly diagnosed HER2-positive metastatic breast cancer
   b. Previously treated HER2-low and HER2-ultralow metastatic breast cancer
   c. Newly diagnosed triple-negative metastatic breast cancer

5. **Which of the following efficacy outcomes was reported in the Phase III DESTINY-Breast06 study?**
   a. No significant difference in progression-free survival (PFS) for HER2-low patients
   b. A statistically significant improvement in PFS for HER2-low patients
   c. An inferior PFS outcome for HER2-low patients